Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imatinib + ranibizumab
- Development stage
- Unknown
- Lead developer
- Vitreous Retina Macula Consultants of New York
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Ophthalmic
01
Overview
This combination therapy consists of oral imatinib mesylate (Gleevec) and intravitreal ranibizumab (Lucentis). It was investigated in a Phase 1 clinical trial sponsored by Vitreous-Retina-Macula Consultants of New York for the treatment of newly diagnosed choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Imatinib is a small molecule tyrosine kinase inhibitor that targets platelet-derived growth factor receptors (PDGFR), which are involved in pericyte recruitment and stabilization of blood vessels. Ranibizumab is a monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A), a key driver of angiogenesis and vascular permeability. The rationale for the combination is to simultaneously inhibit VEGF-mediated vessel growth and PDGF-mediated pericyte protection of those vessels, potentially enhancing the regression of neovascular membranes compared to anti-VEGF monotherapy.
- Brand names
- Gleevec + Lucentis
- Other names
- Imatinib Mesylate / RanibizumabImatinib + Ranibizumab
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on imatinib + ranibizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imatinib + ranibizumab.